35 results on '"Osanto, S"'
Search Results
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
3. Efficacy of enzalutamide in hormone-sensitive metastatic prostate cancer: Clinical utility of 18F-choline PET and whole body MRI
4. Neo-adjUvant veRsus AdjuvaNt chemotherapy in upper tract Urothelial carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”)
5. Predictors for successful downstaging in patients with BCLC intermediate stage hepatocellular carcinoma
6. CRIPTO expression in hepatocellular carcinoma
7. MDT in uro-oncology: Difficult cases in high risk urothelial cancer
8. Addressing changed sexual functioning in cancer patients: A cross-sectional survey among Dutch oncology nurses
9. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10. Phase II Study of Everolimus and Capecitabine in Patients with Locally advanced or Metastatic Hepatocellular Carcinoma (HCC). Results of the first 10 Patients Included
11. Microparticles expressing tissue factor are concurrently released with markers of inflammation and coagulation during human endotoxemia
12. Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism
13. 97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES)
14. Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles
15. PP17 The predictive value of HLA Class I tumor cell expression and tumor infiltration by regulatory T cells for chemotherapy in patients with early breast cancer
16. 49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)
17. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis
18. Non-transferrin bound iron measurement is influenced by chelator concentration
19. 4532 POSTER Bone abnormalities in male germ-cell cancer survivors
20. Microparticle‐associated tissue factor activity: a link between cancer and thrombosis?
21. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study
22. High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients
23. Malignancies, prothrombotic mutations, and the risk of venous thrombosis
24. Deep vein thrombosis associated with central venous catheters – a review
25. Old and new risk factors for upper extremity deep venous thrombosis
26. Malignancies, prothrombotic mutations, and the risk of venous thrombosis
27. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma
28. Risk factors for catheter-related thrombosis in cancer patients
29. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study
30. Chemotherapy-induced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo
31. Prophylaxis with low molecular weight heparin reduces the risk for catheter-related venous thrombosis in cancer patients with centrally but not peripherally inserted central venous catheters for administration of chemotherapy
32. Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer
33. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients
34. Free radicals and antioxidants in chemotherapyinduced toxicity
35. MYOCARDIAL INJURY AFTER INTERLEUKIN-2 THERAPY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.